Pulmonary embolism (PE)

Diagnostic and therapeutic approach

Apixaban (Eliquis)



10mg 2x/day during 7 days, then 5mg 2x/day.


  • Hypersensitivity to the active substance or to any of the excipients.
  • Clinically significant active bleeding.
  • Liver diseases associated with coagulopathy and clinically relevant bleeding risk with severe hepatic impairment (Child Pugh C).
  • Attention to drug interactions and inhibitors of CYP3A4 and / or P-gp.